Shareholder Letters


NEW: AsIDNA™ Letters!

The clinical development of AsiDNA™ is well on its way and we would like to inform you regularly about the progress being made through a Letter dedicated to this first-in-class candidate.


AsiDNA™  Letter No. 2
July 17,  2019

Role of AsiDNA™ in the new combination strategies







AsiDNA™  Letter No. 1
July 4,  2019

The field of DDR and the strategic advantages of AsiDNA™




Last updated on